Title:
DRUG COMBINATION COMPRISING NAFAMOSTAT AND K777 AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/083117
Kind Code:
A1
Abstract:
The present invention provides a drug combination comprising Nafamostat and K777 and a use thereof. The pharmaceutical composition comprises active ingredients, i.e., Nafamostat and K777. The pharmaceutical composition of the present invention can show a remarkable synergistic effect in related research on anti-coronavirus, and shows improvement of the effectiveness of more than 10 times in an anti-novel coronavirus test.
Inventors:
YANG HAITAO (CN)
RAO ZIHE (CN)
WANG HAOFENG (CN)
LIU XIAOCE (CN)
CHEN XINWEN (CN)
XIAO GENGFU (CN)
ZHANG LEIKE (CN)
YANG QI (CN)
JIANG BIAO (CN)
CHEN HONGLI (CN)
PENG WEI (CN)
YANG XIUNA (CN)
RAO ZIHE (CN)
WANG HAOFENG (CN)
LIU XIAOCE (CN)
CHEN XINWEN (CN)
XIAO GENGFU (CN)
ZHANG LEIKE (CN)
YANG QI (CN)
JIANG BIAO (CN)
CHEN HONGLI (CN)
PENG WEI (CN)
YANG XIUNA (CN)
Application Number:
PCT/CN2023/124964
Publication Date:
April 25, 2024
Filing Date:
October 17, 2023
Export Citation:
Assignee:
UNIV SHANGHAI TECH (CN)
GUANGZHOU LABORATORY (CN)
WUHAN INST OF VIROLOGY CHINESE ACADEMY (CN)
GUANGZHOU LABORATORY (CN)
WUHAN INST OF VIROLOGY CHINESE ACADEMY (CN)
International Classes:
A61K31/495; A61K31/215; A61K31/24; A61P31/12; A61P31/14
Domestic Patent References:
| WO2021215798A1 | 2021-10-28 | |||
| WO2021203055A1 | 2021-10-07 | |||
| WO2022047054A2 | 2022-03-03 |
Foreign References:
| JP2021155397A | 2021-10-07 | |||
| CN113336834A | 2021-09-03 |
Other References:
WANG XINLING, XIA SHUAI, WANG QIAN, XU WEI, LI WEIHUA, LU LU, JIANG SHIBO: "Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL (MDPI), BASEL, CH, vol. 21, no. 11, 1 January 2020 (2020-01-01), Basel, CH , pages 3843, XP055783052, ISSN: 1661-6596, DOI: 10.3390/ijms21113843
LIU TIANXIAO; LUO SONGYUAN; LIBBY PETER; SHI GUO-PING: "Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients", PHARMACOLOGY & THERAPEUTICS, ELSEVIER., GB, vol. 213, 26 May 2020 (2020-05-26), GB , XP086249684, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2020.107587
LIU TIANXIAO; LUO SONGYUAN; LIBBY PETER; SHI GUO-PING: "Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients", PHARMACOLOGY & THERAPEUTICS, ELSEVIER., GB, vol. 213, 26 May 2020 (2020-05-26), GB , XP086249684, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2020.107587
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: